Tellimer

GB : Sensyne Health - 2021 ahead of expectations, major inflection in 2022 on-track

Sensyne released a prelim update this morning for FY2021 (year-end April). Revenues of at least £9m were much better than the £8m we had forecast while net cash of £23.6m was seemingly below our £26m forecast but timing effects mean this is more like £27m on a normalised basis. Importantly, on the back of a good start to the year with pharma contract momentum, management provided a positive outlook confirming its confidence in hitting consensus expectations which implies a trebling of revenues to £28m. Lastly, after doubling its patient dataset over the past week to 18m, management is now ambitiously targeting 100m patients by the end of 2024.


Most Viewed See latest
Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers